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ABSTRACT
Introduction Heart transplantation is the gold standard 
treatment for selected patients with end- stage heart 
failure. Although this procedure can improve quality and 
prolong life expectancy, several of these patients persist 
with decreased exercise tolerance. Evidence suggests 
that exercise training can bring multifactorial benefits to 
heart transplant (HTx) recipients. However, it is unclear 
that exercise modality should be preferred. Therefore, the 
aim of this systematic review and network meta- analysis 
is to compare the efficacy and safety of different training 
modalities in HTx recipients.
Methods and analysis We will perform a comprehensive 
literature search in PubMed/MEDLINE, Embase, The 
Cochrane Library, CINAHL, Scopus, SportDISCUS, Web 
of Science Core Collection and PEDro from inception 
until November 2020. Two registries ( ClinicalTrials. gov 
and REBEC) will also be searched for potential results 
in unpublished studies. There will be no restriction on 
language, date of publication, publication status or sample 
size. We will include randomised controlled trials enrolling 
adult HTx recipients with the presence of at least one 
exercise training group, which might be compared with 
another training modality and/or a non- exercise control 
group for a minimum of 4 weeks of intervention. The 
primary outcomes will be peak oxygen consumption and 
occurrence of adverse events. As secondary outcomes, 
the interaction between pulmonary ventilation, pulmonary 
perfusion and cardiac output, oxygen uptake efficiency 
slope, heart rate response, oxygen pulse, peak blood 
pressure and peak subjective perception of effort. In 
addition, we will evaluate the 6 min walking distance, 
health- related quality of life, endothelial function, muscle 
strength, body fat percentage and lean mass. Risk of bias 
will be assessed using the Cochrane RoB V.2.0 tool, and 
we plan to use the Confidence in Network Meta- Analysis 
tool to assess confidence in the results. All materials (raw 
data, processed data, statistical code and outputs) will be 
shared in a public repository.
Ethics and dissemination Given the nature of this 
study, no ethical approval will be required. We believe that 
the findings of this study may show which is the most 
efficacious and safe physical training modality for HTx 
recipients. The completed systematic review and network 
meta- analysis will be submitted to a peer- reviewed 
journal.
PROSPERO registration number CRD42020191192.
INTRODUCTION
Heart transplantation (HTx) is the treatment 
of choice for selected patients with end- stage 
heart failure, representing the pinnacle of 
available therapy.1 Although transplanta-
tion improves quality of life and increases 
life expectancy,2 3 HTx recipients frequently 
experience impaired functional capacity,4 in 
addition to other complications inherent to 
the use of immunosuppressants.5 Reduced 
exercise tolerance, measured by peak oxygen 
consumption (peak VO2), occurs secondary 
to damage to both the central (cardiac and 
pulmonary) and peripheral (vascular and 
skeletal muscle) components.6
In this sense, concomitantly with preven-
tion of HTx- related complications and 
Strengths and limitations of this study
 ► This protocol was guided by Preferred Reporting 
Items for Systematic Review and Meta- Analysis 
Protocols statement, registered in the PROSPERO 
database, and Open Science Framework platform.
 ► We will perform a comprehensive literature review 
with no restrictions on language, publication date, 
publication status or sample size.
 ► The study will be guided by the Cochrane Handbook 
for Systematic Reviews of Interventions, V.6.1, in or-
der to enhance the quality of the study.
 ► A potential limitation, inherent in the methodology of 
this study, is that indirect comparisons provide ob-
servational evidence across randomised trials and 
may suffer from the potential biases of observational 
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control of cardiac risk factors, a structured exercise- based 
rehabilitation programme is recommended and may be 
an adequate strategy to assist in secondary prevention in 
these patients.7–9 Evidence suggests a multifactorial bene-
ficial effect of exercise training (ET) in HTx recipients.6 
Small randomised controlled trials have shown that reha-
bilitation improves autonomic control (both cardiac and 
peripheral),10 muscle strength and body composition,11 
while for endothelial function, synthesis of a small body 
of evidence shows high heterogeneity and the effect 
remains unclear.12 Additionally, in a Cochrane systematic 
review and meta- analysis, ET was efficacious for increasing 
peak VO2.
13 However, considering the broader spectrum 
of exercise interventions, it is unknown whether any 
modality is superior in terms of efficacy or potential for 
harm. In addition, synthesising the effect of ET on other 
clinically relevant outcomes will assist in understanding 
the therapeutic potential of ET in secondary prevention 
in this population.
Different ET modalities have been studied in patients 
after HTx, such as endurance training (moderate- intensity 
continuous and high- intensity interval training),13–15 
resistance training11 16 and the combination of both.17 18 
Indeed, combined ET is the most recommended modality 
for cardiovascular rehabilitation, despite the lack of 
robust evidence of its superiority over other modalities in 
this specific population.8 9 In addition, there is little infor-
mation about the characteristics of ET (eg, frequency, 
intensity, volume and type) as well as differences in adap-
tation depending on whether training is begun early or 
late after surgery. Even less is known about the true effect 
of ET on other relevant parameters beyond peak VO2 in 
the HTx scenario.
In patients with heart failure, some variables measured 
by cardiopulmonary exercise testing (CPET), such as 
peak VO2, the ratio of minute ventilation (VE) to carbon 
dioxide production (VE/VCO2 slope)
19 20 and heart rate 
(HR) recovery after ET21 were identified as important 
prognostic markers. However, in HTx, the evidence base 
is much less clear. In a retrospective study, peak VO2 
and self- reported functional capacity were found to be 
strong predictors of survival in HTx recipients.22 In turn, 
muscle strength and body fat seem to influence exercise 
capacity.23 Interestingly, while the main limiting symptom 
for ET before HTx was dyspnoea, after the procedure, 
patients reported interruption of exercise due to leg 
fatigue and muscle exhaustion.4 In addition, another 
important factor is the chronotropic response to ET24 due 
to the involvement of a denervated heart in increasing 
HR, contributing to the reduction of exercise tolerance 
and influencing adaptations to ET.25 26
In this systematic review and network meta- analysis, we 
will compare the safety and efficacy of different modal-
ities of ET based on peak VO2 improvement. Further-
more, we will quantify the effect of ET on important 
outcomes that have not yet been scrutinised, while 




 ► To compare the efficacy of different ET modali-
ties (moderate- intensity continuous training, high- 
intensity interval training, resistance training and 
combined aerobic plus resistance training considering 
both centre- based and home- based ET) in improving 
peak VO2 in HTx recipients;
 ► To compare rates of adverse events, such as vertigo, 
dizziness, musculoskeletal complaints, syncope, 
hypotension, elevated blood pressure or cardiovas-
cular events (angina, arrhythmias, myocardial infarc-
tion, stroke and death), during and after sessions of 
different ET modalities.
Secondary objectives
 ► To compare quantitatively, through meta- analysis (ET 
vs usual care) and, if possible, through network meta- 
analysis, the efficacy of moderate- intensity continuous 
training, high- intensity interval training, resistance 
training and combined training (centre- based and 
home- based ET) in regards to the following varia-
bles: VE/VCO2 slope, oxygen uptake efficiency slope 
(OUES), HR (rest, peak and recovery), peak oxygen 
pulse (VO2/HR), peak systolic and diastolic blood 
pressure, Borg Rating of Perceived Exertion scale, 
6 min walk test distance, health- related quality of life, 
endothelial function, muscle strength and fat and 
lean mass percentage.
 ► To compare quantitatively, through meta- analysis 
(ET vs usual care), the efficacy and safety of ET in 
the following subgroups: patients after recent (<6 
months) versus late HTx and those receiving centre- 
based versus home- based ET as well as at different 
follow- up periods.
METHODS
This protocol was guided by the Preferred Reporting Items 
for Systematic Review and Meta- Analysis Protocols (PRIS-
MA- P) 2015 statement27 (see checklist in online supple-
mental material 1) and the PRISMA- P 2015 Explanation 
and Elaboration Document.28 The same documents, as 
well as the PRISMA Extension for Network Meta- Analysis 
of Health Care Interventions,29 will be used to prepare 
the final report. In addition, the study will be conducted 
according to the Cochrane Handbook for Systematic 
Reviews of Interventions V.6.1.30 This systematic review and 
network meta- analysis were registered in the International 
Prospective Register of Systematic Reviews. All study mate-
rials will be shared publicly through the Open Science 
Framework tool, available at: https:// osf. io/ 3rwxb/.
Eligibility criteria
This systematic review will be based on population, inter-
vention, comparator, outcome and setting criteria.
Participants
(a) HTx recipients aged ≥18 years, regardless of sex and 
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according to the transplant centre protocol, who did not 
experience severe complications or high- grade rejec-
tion on cardiac biopsies during the ET period. Studies 
enroling heterotopic transplant recipients or multiorgan 
transplant recipients will be excluded.
Interventions
We will consider ET as a single strategy or as a component 
of a comprehensive cardiac rehabilitation programme 
(after hospital discharge), considering a minimum inter-
vention period of 4 weeks. Centre- based and home- based 
interventions will also be considered for the following 
modalities: moderate- intensity continuous training, 
high- intensity interval training, resistance training and 
combined training (aerobic plus resistance).
Comparators
For network meta- analysis, by the very nature of this study, 
we will compare the eligible interventions among them-
selves. For the parallel meta- analysis, we will compare 
the interventions with their respective control groups 
(non- ET or usual care).
Outcomes
Primary outcomes
Peak VO2 measured through CPET in L/min and mL/
kg/min, whenever available. Rate of adverse events 
through the absolute and relative frequency of occur-
rences described in the safety outcomes.
Secondary outcomes
Other CPET variables: VO2/HR in mL/beat and both 
slopes, VE/VCO2 slope and OUES as absolute measures. 
HR (rest, peak and recovery) in beats/min, peak systolic 
and diastolic blood pressure in mm Hg and Borg Rating 
of Perceived Exertion score. Other secondary outcomes: 
6 min walk distance (in metres), health- related quality of 
life using validated instruments (eg, the 36- Item Short- 
Form Health Survey and WHO Quality of Life question-
naire) and endothelial function by absolute (mm) and 
relative (%) flow- mediated dilation. Upper and lower 
extremity maximal strength in kilograms assessed using 
one- repetition maximum (1RM) testing or another equiv-
alent method (eg, isokinetic evaluation (Nm), sit- to- stand 
movements in 1 min and hand grip strength test). Rela-
tive (%) and absolute (kg) fat mass and lean mass, prefer-
ably measured through dual- energy X- ray absorptiometry 
or bioelectrical impedance analysis.
Safety outcomes
Whenever data are available in the randomised controlled 
trial, we will quantitatively analyse the occurrence of 
adverse events—such as vertigo, dizziness, musculoskel-
etal complaints, syncope, hypotension, elevated blood 
pressure or cardiovascular events (angina, arrhythmias, 
myocardial infarction, stroke and death)—during and 
after exercise sessions.
Study designs
Only randomised controlled trials (parallel- group, cross-
over or cluster design) will be included. Crossover trials 
will be considered in their full form only if there is a 
washout period of at least 4 weeks. No restrictions will be 
imposed on language or date of publication.
Information sources and search
Electronic search strategies
For a comprehensive survey of the literature, the 
following databases from inception to November 2020 
will be searched: PubMed/MEDLINE, Cochrane Library, 
Embase, the Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), Scopus, SportDISCUS, 
Web of Science Core Collection and Physiotherapy 
Evidence Database (PEDro). Two registries ( Clinical-
Trials. gov and REBEC) will also be searched for poten-
tial results in unpublished studies. We will also review the 
grey literature, which includes repositories of disserta-
tions and theses, conference publications and preprint 
repositories and databases. Authors will be contacted if 
further data are required. A hand search of the reference 
lists of included studies will be also conducted.
Search strategy
The main electronic search strategy was designed for 
PubMed/MEDLINE and will be adapted as appropriate 
for each of the other databases. Queries will be devel-
oped using Medical Subject Headings (MeSH) terms and 
their synonyms and Boolean operators (where possible) 
to improve searches. Keywords and MeSH terms include: 
‘heart transplantation’, ‘exercise’, ‘resistance training’, 
‘physical endurance’ and ‘circuit- based exercise’. 
Comprehensive search strategies for all the databases that 
will be consulted are included in the online supplemental 
material 2.
Study records
Data managements and selection process
Data extraction will be based on the following steps: 
(1) In Clarivate Analytics Endnote X9 (2018) reference 
management software, the reviewer (FF) will set up a 
library to gather all studies retrieved from the aforemen-
tioned databases, (2) all duplicates will be excluded, (3) 
the titles and abstracts will be evaluated by two indepen-
dent reviewers (FF and JBdL) for classification as poten-
tially eligible or non- eligible. Divergences will be solved 
by consensus between reviewers, and, if necessary, a third 
opinion (RS) will be requested, (4) studies classified as 
potentially eligible will be read in full and discrepan-
cies will be solved by the same previous method, (5) the 
studies excluded in the previous stage will be compiled in 
an Excel worksheet, followed by their respective reasons 
for exclusion (no design of interest, no population of 
interest, no intervention of interest, no endpoints of 
interest or other). The results of the selection process will 
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Data collection process and data items
Data will be extracted by two independent reviewers (FF 
and JBdL). Disagreements will be solved by consensus, 
and, if necessary, a third opinion (RS) will be requested. 
The reviewers will not be blinded to the authors’ names, 
institutions or periodicals. The following information will 
be extracted:
 ► Study characteristics: first author, journal’s name, year 
of publication, conflict of interest, publication type, 
study design (parallel, crossover or cluster randomised 
controlled trial), washout period (weeks), study 
period (weeks), country, language of the publication 
and number of patients randomised;
 ► Patient baseline characteristics: age, weight, height, 
body mass index, sex, time since transplantation, 
immunosuppressant therapy, comorbidities, aetiology 
and duration of heart failure, surgical technique, 
previous exercise- based rehabilitation (phase 1) 
and presence of possible additional interventions to 
training; in addition, outcome assessment methods; 
equipment used (cycle ergometer or treadmill) 
and peak respiratory exchange ratio, when CPET is 
performed;
 ► Interventions and comparators: training modality, 
material resources, intended target zone and form of 
intensity control, session volume, weekly frequency 
and follow- up period; supervisory level information, if 
centre- based or home- based ET.
 ► Results: number of participants in each group, 
preintervention and postintervention values, deltas, 
standard deviations or other measures of dispersion 
and p values.
Geometry of the network
The forest.netmeta function of the netmeta package will 
be used to build and present the geometry of different 
interventions. In the graph, nodes will be used to repre-
sent the intervention and edges to show comparisons 
between interventions. Besides qualitative descriptions 
and graphs, we will provide quantitative metrics assessing 
features of network geometry, such as diversity, co- occur-
rence and homophily.
Risk of bias within individual studies
The risk of bias will be assessed using the Cochrane 
RoB V.2.0 tool.31 The assessment of the studies will be 
performed independently by two reviewers (DdSS and 
SATL); any disagreements will be resolved by consensus 
or by discussion with a third researcher (JBdL). Evalu-
ation of quality will be divided into five items: (1) bias 
arising from the randomisation process, (2) bias due to 
deviations from intended interventions, (3) bias due to 
missing outcome data, (4) bias in measurement of the 
outcome, (5) bias in selection of the reported result. Also, 
the risk of bias will be classified into three categories: (1) 
low risk of bias, (2) some concerns and (3) high risk of 
bias.
Publication bias
To investigate the influence of small- study effects, we will 
use the visual inspection method of funnel plot if at least 




We will use difference in means as the principal summary 
measure of the effect to express comparisons between 
interventions, associated with the 95% confidence interval 
as a measure of uncertainty. When the same outcome is 
presented by different measures, the standardised mean 
difference will be applied. As a summary measure of 
dichotomous variables, we will use the risk ratio. If quan-
titative synthesis is not appropriate, a systematic narrative 
synthesis will be provided.
For continuous variables, we will extract the mean (or 
other measure of central tendency) and standard devia-
tion (or other measure of dispersion) of variables at base-
line and in the follow- up in each arm of the studies. When 
available, we plan to obtain the mean change from base-
line and SD or other measures of dispersion in each arm 
of the trials. For dichotomous outcomes, we will collect 
absolute and relative frequencies in each treatment arm.
Planned methods of analysis
We plan to use the netmeta package V.1.2–1 implemented 
in R V.3.6.2 software for Mac to perform a network meta- 
analysis33 and synthesise direct and indirect evidence 
of the therapeutic effects of the interventions. Node- 
splitting method will be used to assess inconsistencies 
between direct and indirect comparisons when observing 
a loop connecting three arms. We will present a treatment 
ranking by p scores based on the point estimates and stan-
dard error of the available network.
Additional analyses
We plan to perform analyses to compare quantitatively, 
through meta- analysis (ET vs usual care), the efficacy and 
safety of ET in two subgroups: patients after recent (less 
than 6 months) versus late HTx and centre- based versus 
home- based ET as well as different follow- up periods. 
In case of significant heterogeneity or inconsistency, a 
subgroup analysis will be performed to explore, when 
possible, the following variables: age, sex and comorbidi-
ties. Finally, a sensitivity analysis will be performed for the 
inclusion of studies with high risk of bias and/or missing 
data.
Risk of bias across studies
We plan to use the Confidence in Network Meta- Analysis 
(CINeMA) tool34 35 to assess confidence in the results. 
CINeMA considers six domains—within- study bias, 
reporting bias, indirectness, imprecision, heterogeneity 
and incoherence—and assigns judgements at three levels 
(no concerns, some concerns or major concerns). For 
each treatment effect, adjudicate levels of confidence 
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Assessment, Development, and Evaluation assessments of 
very low, low, moderate, or high will be used.
Patient and public involvement
No patient involved.
Ethics and dissemination
Given the nature of this study, no ethical approval will be 
required. The completed systematic review and network 
meta- analysis will be submitted to a peer- reviewed journal.
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